Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

Phase 2 Completed 31 enrolled Boehringer Ingelheim Eli Lilly and Company · collab

RandomizedCrossoverDouble-blindTreatment

Summary

This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.

Timeline

Start: 2016-05-10
Primary completion: 2017-12-19
Completion: 2019-07-02

Outcome

Met primary endpoint

paper Combination treatment with empagliflozin-ramipril resulted in an 8 mL/min/1.73 m2 lower GFR compared with placebo-ramipril treatment (P=0.0061) PMID 35862082 ↗

Publications

Lytvyn Y, Kimura K, Peter N, Lai V, Tse J, Cham L, Perkins BA, Soleymanlou N, Cherney DZI. Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition. Circulation. 2022 Aug 9;146(6):450-462. doi: 10.1161/CIRCULATIONAHA.122.059150. Epub 2022 Jul 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Empagliflozin	Small molecule	25 mg	—
Background	Ramipril	Small molecule	10 mg	—